In the neoadjuvant and adjuvant phases of arm C, pembrolizumab will be administered on day 1 and enfortumab vedotin will be administered on days 1 and 8 of each cycle. Enrollment is complete for arm A ...

Merkel cell carcinoma (MCC) incidence and mortality have stabilized in the United States (US) in recent years, and improved survival is linked with diagnosis within the last decade, according to study ...

For our analysis using the SEER database, the following criteria were applied to include patients: (1) diagnosis of primary UTUC between January 2004 and December 2015; (2) histological type of ...

meaning 10 patients either showed no signs of cancer after treatment or their cancer cell burden was reduced significantly. Eight out of 11 patients (72.7%) achieved complete remission.

Background: Urinary tract squamous cell carcinoma (UTSCC) is a rare disease, comprising approximately 3% of histological subtypes from the bladder and urinary tract. Limited data exist to support ...

Ipilimumab and nivolumab in patients with metastatic clear cell renal cell carcinoma (mccRCC) treated on the phase 3 PDIGREE ... (BCG) in BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC ...

Lung Squamous cell carcinoma (LSCC) represents the second most common non-small cell lung cancer. Although studies identified adenocarcinoma-like driver mutations in LSCC using next-generation ...